基于高三尖杉酯碱的诱导方案治疗老年急性髓系白血病：来自中国单中心的经验。
A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.
机构信息
Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, PR China.
出版信息
J Hematol Oncol. 2009 Jul 30;2:32. doi: 10.1186/1756-8722-2-32.
BACKGROUND AND PURPOSE
The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine, in combination with cytarabine as an induction therapy for AML in elderly patients (> or =60 years).
RESULTS
Twenty-three patients were treated with the HA regimen consisting of homoharringtonine (2 mg/m2/day for 7 days) and cytarabine (Ara-C, 100 mg/m2/day for 7 days). The overall response rate was 56.5% with complete remission (CR) rate of 39.1% and partial remission of 17.4%. There was no early death in this cohort of patients. The estimated median overall survival (OS) time of all patients was (12.0 +/- 3.0) months. The estimated OS time of the CR patients was 15 months. The estimated one-year OS rate of all patients treated with HA protocol was (49.3 +/- 13.5) %. The estimated one-year OS rate of the CR patients was (62.5 +/- 17.1) %.
CONCLUSION
HA is a suitable induction regimen for elderly patients with AML, with relatively low toxicity and reasonable response rate.
背景与目的
老年急性髓系白血病（AML）患者对缓解诱导治疗的反应仍较差。本文旨在评估植物生物碱高三尖杉酯碱（homoharringtonine）联合阿糖胞苷（cytarabine）作为老年（≥60 岁）AML 患者诱导治疗的疗效和毒性。
结果
23 例患者接受了 HA 方案治疗，该方案由高三尖杉酯碱（2 mg/m2/天，连用 7 天）和阿糖胞苷（Ara-C，100 mg/m2/天，连用 7 天）组成。总体缓解率为 56.5%，完全缓解（CR）率为 39.1%，部分缓解率为 17.4%。该患者队列中无早期死亡。所有患者的估计中位总生存期（OS）时间为（12.0±3.0）个月。CR 患者的估计 OS 时间为 15 个月。接受 HA 方案治疗的所有患者的估计 1 年 OS 率为（49.3±13.5）%。CR 患者的估计 1 年 OS 率为（62.5±17.1）%。
结论
HA 是老年 AML 患者的一种合适的诱导方案，具有相对较低的毒性和合理的缓解率。
Zotero 插件